Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...
Cytokinetics initiated with a Buy at Stifel
Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...
pharmaphorum3d
Cytokinetics eyes go-it-alone strategy for aficamten
In a statement, Cytokinetics said that part of the Royalty Pharma cash will go towards the commercial launch of cardiac myosin inhibitor aficamten, which is being prepared for filing in the US and ...
pharmaphorum3d
Cytokinetics' heart drug omecamtiv strikes out in heart failure trial
Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.
Stifel starts Cytokinetics stock with Buy, $80 target
Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...
Morningstar10d
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its ...
Business Insider1mon
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of ...